Written question asked by Lord Clement-Jones (Liberal Democrat), in the House of Lords. It was due for an answer on Friday, 4 July 2003. It was answered by Lord Warner (Labour) on Friday, 4 July 2003.
Warner, Lord
- Question
- Why they are not funding a commercially available fresh frozen plasma which is treated in such a way that there is no risk of SARS, or other unknown, potentially fatal emerging (lipid-enveloped) viruses, being transmitted; and why they will not consider funding a pharmaceutically licensed, virally inactivated, pooled, fresh frozen plasma, which could eliminate the risk to patients of transfusion-related acute lung injury (TRALI) and the risk of infections such as HIV, hepatitis B and hepatitis C. [HL 3488] [HL 3491].
Secondary information
- Type
- Written question
- Reference
- HL 3488; 650 c151-2WA
- Session
- 2002-03
- Subjects
- Contamination Blood Health hazards Disease control HIV/AIDS Hepatitis Safety Side effects Viral diseases SARS Blood transfusions Respiratory diseases
Librarians' tools
- Timestamp
- 2013-11-25 07:21:13 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_859577
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_859577
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_859577